Mary Beth Blauwet
YOU?
Author Swipe
View article: Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites
Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites Open
View article: Influence of calcium administration on the short-term hemodynamic and anti-ischemic effects of nifedipine
Influence of calcium administration on the short-term hemodynamic and anti-ischemic effects of nifedipine Open
This prospective study investigated whether pretreatment with intravenously administered calcium would influence the effect of nifedipine on rest hemodynamics and treadmill performance in patients with ischemic heart disease. Seventeen pat…
View article: Identification of false positive exercise tests with use of electrocardiographic criteria: A possible role for atrial repolarization waves
Identification of false positive exercise tests with use of electrocardiographic criteria: A possible role for atrial repolarization waves Open
Atrial repolarization waves are opposite in direction to P waves, may have a magnitude of 100 to 200 mu V and may extend into the ST segment and T wave. It was postulated that exaggerated atrial repolarization waves during exercise could p…
View article: Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study Open
This large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
View article: Relation Between Gender, Etiology and Survival in Patients With Symptomatic Heart Failure
Relation Between Gender, Etiology and Survival in Patients With Symptomatic Heart Failure Open
OBJECTIVES: This study investigated the relation between gender, etiology and survival in patients with symptomatic heart failure. BACKGROUND: Previous work provides conflicting results concerning the relation between gender, clinical char…
View article: <p>Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial</p>
Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial Open
NCT03056690.
View article: Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial
Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial Open
Four-week treatment with ASP7962 (100 mg BID) did not improve pain or physical function in individuals with painful knee osteoarthritis. ClinicalTrials.gov, NCT02611466; EudraCT Number, 2014-004996-22.
View article: Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies
Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies Open
Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a similar prevalence of storage symptoms as women. The efficacy and safety of once-daily mirabegron 50 mg was evaluated in male OAB patients …
View article: Patient‐reported outcomes with the β<sub>3</sub>‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
Patient‐reported outcomes with the β<sub>3</sub>‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder Open
Aims To assess patient‐reported outcomes (PROs) in patients with overactive bladder (OAB) receiving the novel β 3 ‐adrenoceptor agonist mirabegron. Methods Data from a randomised, double‐blind, controlled phase III trial in 1,987 patients …
View article: The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials Open
The improvements in objective measures seen with mirabegron 50 mg translate into a meaningful clinical benefit as evident by the directional consistency seen in HRQoL measures of benefit.